The potential of different miRNAs to alter the expression of the mammalian target of rapamycin (mTOR)/protein kinase B (PKB or AKT)/phosphatidylinositol‐3‐kinase (PI3K) signaling cascade, a key pathway in the progression of acute myeloid leukemia (AML), has been demonstrated across different types of cancers. Here, AKT1 is linked to acute myeloid leukemia.